First, because CXCL12 up regulates CD164 expression and stimulates prostate cancer cell proliferation and adhesion, therapies designed to disrupt CD164 or the CXCL12/CXCR4 axis could be used to alter tumor progression via several mechanisms. Here, CD164 is linked to neoplasm.